US2016220617A1PendingUtilityA1

Methods for treating cartilage disorders, diseases and injuries

48
Assignee: NOVEOME BIOTHERAPEUTICS INCPriority: May 17, 2013Filed: Apr 11, 2016Published: Aug 4, 2016
Est. expiryMay 17, 2033(~6.8 yrs left)· nominal 20-yr term from priority
Inventors:Donna M OlejniczakDavid L. SteedRandall G. RuppGeorge L. Sing
A61K 9/0085A61K 35/50
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.

Claims

exact text as granted — not AI-modified
1 .- 9 . (canceled) 
     
     
         10 . A method for treating cartilage diseases, disorders and injuries in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a composition selected from the group consisting of a Cellular Factor-containing Solution (CFS) composition, Amnion-derived Multipotent Progenitor (AMP) cells, AMP-nucleus pulposus (NP) cells and AMP-annulus fibrosus (AF) cells. 
     
     
         11 . The method of  claim 10  wherein the treatment reduces the inflammation associated with cartilage diseases, disorders and injuries. 
     
     
         12 . The method of  claim 10  wherein the CFS composition is selected from the group consisting of Amnion-derived Cellular Cytokine Solution (ACCS), ACCS-nucleus pulposus (NP) and ACCS-annulus fibrosus (AF). 
     
     
         13 . The method of  claim 10  wherein the cartilage disease, disorder or injury is selected from the group consisting of osteoarthritis, rheumatoid arthritis, gouty arthritis, psoriatic arthritis, intervertebral disc herniation, degenerative disc disease, spinal stenosis, lumbar scoliosis, chondrodystrophies, traumatic rupture or detachment, achondroplasty, costochondritis, relapsing polychonditis destruction, and ankylosing spondylitis. 
     
     
         14 . A method for promoting the growth or enhancing the survival of NP cells in a degenerating intervertebral disc comprising administering to the degenerating intervertebral disc a therapeutically effective amount of a composition selected from the group consisting of a CFS composition, AMP cells, AMP-NP cells, and AMP-AF cells. 
     
     
         15 . The method of  claim 14  wherein the CFS composition is selected from the group consisting of ACCS, ACCS-NP and ACCS-AF. 
     
     
         16 . A method for preventing degradation of extracellular matrix in cartilage comprising administering to the cartilage a therapeutically effective amount of a composition selected from the group consisting of a CFS composition, AMP cells, AMP-NP cells and AMP-AF cells. 
     
     
         17 . The method of  claim 16  wherein the CFS composition is selected from the group consisting of ACCS, ACCS-NP and ACCS-AF. 
     
     
         18 . A composition selected from the group consisting of AMP-NP cells, AMP-AF cells, ACCS-NP, and ACCS-AF.

Join the waitlist — get patent alerts

Track US2016220617A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.